STOCK TITAN
  1. Home
  2. News
  3. HOOK

HOOKIPA Pharma Inc. - HOOK STOCK NEWS

Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.

HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.

VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.

HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.

In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.

As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.

News

HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

Rhea-AI Summary

HOOKIPA Pharma Inc. reported its first quarter 2024 financial results and business highlights, focusing on its pivotal trial design for HB-200 in combination with pembrolizumab for HPV16+ recurrent or metastatic OPSCC. The company received FDA clearance for its IND application for HB-700 for KRAS mutated cancers. Financially, HOOKIPA saw total revenues of $36.6 million, driven by milestone payments, resulting in a profitable quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

Rhea-AI Summary
HOOKIPA Pharma announced the final pivotal Phase 2/3 trial design for HB-200 in combination with pembrolizumab. The trial is for the first-line treatment of patients with HPV16+ recurrent or metastatic oropharyngeal squamous cell carcinoma. The Company has aligned with the FDA and anticipates enrolling the first patient in Q4 2024. The data will be presented at ASCO 2024 Annual Meeting, with two additional abstracts accepted. HOOKIPA's CEO expressed confidence in the trial design and potential for accelerated approval based on favorable results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.18%
Tags
clinical trial
-
News

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers

Rhea-AI Summary
HOOKIPA Pharma announced FDA clearance of its Investigational New Drug Application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. The program targets five prevalent KRAS mutations in lung, colorectal, pancreatic, and other cancers, potentially benefiting more patients than single mutation inhibitors. The IND submission resulted in a $10 million milestone payment from Roche, giving HOOKIPA full control of the intellectual property portfolio and collaboration rights for the HB-700 program. Preclinical data will be presented at the ASCO 2024 Annual Meeting, showcasing the company's commitment to advancing oncology treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
clinical trial
News

HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
HOOKIPA Pharma Inc. grants 250,000 non-statutory options to its Chief Development Officer, Mark Winderlich, under the 2023 Inducement Plan. The options have an exercise price of $0.76 per share, a ten-year term, and vest over four years. This award was granted as an inducement material to Winderlich's acceptance of employment with HOOKIPA in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.8%
Tags
none
-
News

HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration

Rhea-AI Summary
HOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumab, receiving PRIME designation from EMA. Investor call scheduled to discuss regulatory interactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
conferences
-
News

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Rhea-AI Summary
HOOKIPA Pharma Inc. reports promising Phase 2 data for HB-200 in combination with pembrolizumab for head and neck cancers. They are finalizing IND activities for HB-700 and progressing on infectious disease programs. Financially, they have a strong cash position of $117.5 million at year end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
earnings
News

HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference

Rhea-AI Summary
HOOKIPA Pharma Inc. (HOOK) CFO to present at Leerink Partners Global Biopharma Conference 2024. The company focuses on immunotherapeutics using its proprietary arenavirus platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
conferences
-
News

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Rhea-AI Summary
HOOKIPA Pharma Inc. announced strategic priorities to focus on advancing clinical programs for HPV16+ head and neck cancers and Gilead-partnered infectious disease programs. The company will prioritize the clinical development of a randomized trial for HB-200 in HPV16+ head and neck squamous cell carcinoma, implement cost-saving initiatives, and reduce its workforce by 30 percent. HOOKIPA will also regain global development rights to HB-700 program for KRAS-mutated cancers from Roche and maintain a strong cash position of $117.5 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.13%
Tags
partnership
-
News

HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization

Rhea-AI Summary
HOOKIPA Pharma Inc. appoints Mark Winderlich, PhD, as Chief Development Officer, effective April 1, 2024. Dr. Winderlich brings extensive experience in leading drug development processes and will focus on advancing the HB-200 program to improve the standard of care for people with advanced HPV16+ head and neck cancer. He joins HOOKIPA from Evotec SE, where he led the partnership with Bristol Myers Squibb in oncology and played key roles in the development of multiple drug candidates. Dr. Winderlich's appointment reflects HOOKIPA's commitment to advancing novel arenaviral therapies for cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.15%
Tags
management clinical trial
News

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced that Gilead Sciences has purchased 15 million shares of HOOKIPA’s common stock for approximately $21.25 million, at a price of $1.4167 per share. Following the transaction, Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock. The equity investment aims to advance the Gilead-partnered HIV therapeutic program through Phase 1, with the trial expected to commence in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.74%
Tags
none

FAQ

What is the current stock price of HOOKIPA Pharma (HOOK)?

The current stock price of HOOKIPA Pharma (HOOK) is $1.99 as of January 22, 2025.

What is the market cap of HOOKIPA Pharma (HOOK)?

The market cap of HOOKIPA Pharma (HOOK) is approximately 24.1M.

What does HOOKIPA Pharma Inc. specialize in?

HOOKIPA Pharma Inc. specializes in developing immunotherapeutics targeting infectious diseases and cancer using its proprietary arenavirus platform.

What are VaxWave® and TheraT®?

VaxWave® and TheraT® are proprietary technologies developed by HOOKIPA to stimulate the immune system. VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector.

How do the arenavirus technologies work?

The technologies reprogram the immune system to induce pathogen-neutralizing antibodies and CD8+ T cells, effectively targeting and neutralizing infectious agents and cancer cells.

What recent achievements has HOOKIPA made?

HOOKIPA has successfully completed a Phase 1 clinical trial and is advancing its pipeline with new immunotherapies for HPV16-positive oropharyngeal cancer and KRAS mutant cancer.

How are HOOKIPA's viral vectors administered?

HOOKIPA's viral vectors are administered systemically, targeting dendritic cells in vivo and activating the immune system to combat diseases.

What is the financial condition of the company?

As of December 31, 2023, HOOKIPA maintains a strong financial position, supporting its ongoing research and development efforts.

What is the significance of TheraT® in cancer treatment?

TheraT® induces CD8+ T cell responses to tumor antigens, achieving frequencies and potencies that match or exceed those observed in adoptive T cell therapy, making it significant for cancer treatment.

Who can be contacted for investor relations?

For investor relations, Michael Kaiser can be contacted at michael.kaiser@hookipapharma.com or +1 (917) 984 7537.

What are the upcoming projects for HOOKIPA?

Upcoming projects include the continued development of arenavirus-based immunotherapies for various cancers, including KRAS mutant cancer and HPV16-positive oropharyngeal cancer.

What makes HOOKIPA's technologies unique?

HOOKIPA's technologies are unique because they allow repeated administration while maintaining efficacy, and they target dendritic cells to activate the immune system effectively.
Stock HOOK logo
HOOKIPA Pharma Inc.

Nasdaq:HOOK

HOOK Rankings

#5289 Ranked by Market Cap
N/A Ranked by Dividends

HOOK Stock Data

24.11M
7.59M
21.44%
37.16%
0.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK